8-K filed February 23, 2026, 6:59 PM ET ticker VIR CIK 0001706431

other material confidence high sentiment positive materiality 0.95

Vir Biotechnology enters global strategic collaboration with Astellas for VIR-5500 prostate cancer T-cell engager

Vir Biotechnology, Inc.

Vir Bio will receive $335 million in upfront and near-term payments, including $240M cash and $75M equity at 50% premium.
Eligible for up to $1.37 billion in development, regulatory and sales milestones plus tiered double-digit royalties on ex-U.S. net sales.
Global development costs shared 40% Vir Bio / 60% Astellas; U.S. profits/losses split 50/50 with Vir co-promotion option.
Phase 1 data for VIR-5500 shows dose-dependent anti-tumor activity; oral presentation at ASCO GU 2026 on February 26.
Cash and investments $781.6M as of Dec 31, 2025; net loss for full year 2025 was $438.0 million.

item 1.01 item 2.02 item 3.02 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001628280-26-010740
form_type: 8-K
ticker: VIR
cik: 0001706431
company_name: Vir Biotechnology, Inc.
filed_at: 2026-02-23T23:59:59+00:00
discovered_at: 2026-05-14T18:02:35.951469+00:00
generated_at: 2026-05-16T01:12:35.315312+00:00
sec_items: ["1.01", "2.02", "3.02", "8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001628280-26-010740
json_url: https://secwatch.observer/filing/0001628280-26-010740.json
markdown_url: https://secwatch.observer/filing/0001628280-26-010740.md
text_url: https://secwatch.observer/filing/0001628280-26-010740.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1706431/000162828026010740/0001628280-26-010740-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1706431/000162828026010740/vir-20260219.htm
generated_by_model: deepseek-v4-flash:cloud
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source-grounded claims

2e82a69080506ca159674129ebb1b998d5a851c7

Vir Biotechnology, Inc. entered into Collaboration and License Agreement with Astellas US LLC valued at $335 million in upfront and near-term milestone payments (effective 2026-02-19).

On February 19, 2026, Vir Biotechnology, Inc. (Vir Bio) and Astellas US LLC (together with its subsidiaries and affiliates (including its indirect parent, Astellas Pharma Inc.), Astellas) entered into a Collaboration and License Agreement (the Agreement).

SEC 8-K Item 1.01/1.02 confidence 0.9 SEC evidence

3ab58c2082c0337f6333f1ede5c2f6277aa94382

Vir Biotechnology, Inc. entered into Stock Purchase Agreement with Astellas US LLC valued at approximately $75 million (effective 2026-02-19).

Concurrently with the execution of the Agreement, Vir Bio also entered into the SPA, pursuant to which Astellas has agreed to purchase 7,239,382 shares of Vir Bio’s common stock, par value $0.0001 per share (Common Stock), for an aggregate purchase price of approximately $75 million, subject to customary closing conditions.

SEC 8-K Item 1.01/1.02 confidence 0.9 SEC evidence

Comparable filings

CLRB

Cellectar raises ~$35M via stock/warrant offering; reports positive 12-mo Phase 2b WM data

Cellectar Biosciences, Inc. May 8, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 8.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 3.02, 8.01, 9.01 same event type: other_material similar materiality

This filing

On February 19, 2026, Vir Biotechnology, Inc. (Vir Bio) and Astellas US LLC (together with its subsidiaries and affiliates (including its indirect parent, Astellas Pharma Inc.), Astellas) entered into a Collaboration and License Agreement (the Agreement).

Comparable filing

pursuant to an additional securities purchase agreement with certain members of the executive management team of the Company (the “Management Purchase Agreement”

Filing page SEC filing

GPCR

Structure Therapeutics Amends Sales Agreement to Raise ATM Capacity to $400M and Reports Q1 2026 Financials

Structure Therapeutics Inc. May 7, 2026, 7:59 PM ET other_material Items 1.01, 2.02, 8.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 2.02, 8.01, 9.01 same event type: other_material similar materiality

This filing

On February 19, 2026, Vir Biotechnology, Inc. (Vir Bio) and Astellas US LLC (together with its subsidiaries and affiliates (including its indirect parent, Astellas Pharma Inc.), Astellas) entered into a Collaboration and License Agreement (the Agreement).

Comparable filing

On May 7, 2026, Structure Therapeutics Inc. (the “Company”) amended and restated that certain Sales Agreement dated August 6, 2025 (the “Sales Agreement” and as amended and restated, the “Amended and Restated Sales Agreement”) with Leerink Partners LLC and Cantor Fitzgerald & Co. (collectively, the “Sales Agents”), relating to the offer and sale of the Company’s American Depositary Shares (“ADSs”), each representing three ordinary shares, $0.0001 par value per ordinary share.

Filing page SEC filing

SUJA

Suja Life completes IPO of 8.9M shares at $21/share; closes May 8, 2026

SUJA LIFE, INC. May 8, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 3.03, 5.03, 5.02, 9.01

same fact type: material_agreement same SEC item: 1.01, 3.02, 9.01 same event type: other_material similar materiality

This filing

On February 19, 2026, Vir Biotechnology, Inc. (Vir Bio) and Astellas US LLC (together with its subsidiaries and affiliates (including its indirect parent, Astellas Pharma Inc.), Astellas) entered into a Collaboration and License Agreement (the Agreement).

Comparable filing

On May 6, 2026, Suja Life, Inc. (the “Company”) and Suja Life Holdings, L.P. (“Holdings LP”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, Jefferies LLC, and William Blair & Company, L.L.C., as representatives of the several underwriters named therein (collectively, the “Underwriters”) relating to the initial public offering (the “IPO”) of the Company’s Class A common stock

Filing page SEC filing

AREB

American Rebel exchanges $1.77M preferred & note for ~5.97M common shares to Streeterville

AMERICAN REBEL HOLDINGS INC May 8, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 9.01

same fact type: material_agreement same SEC item: 1.01, 3.02, 9.01 same event type: other_material similar materiality

This filing

On February 19, 2026, Vir Biotechnology, Inc. (Vir Bio) and Astellas US LLC (together with its subsidiaries and affiliates (including its indirect parent, Astellas Pharma Inc.), Astellas) entered into a Collaboration and License Agreement (the Agreement).

Comparable filing

Streeterville Series E Preferred Exchange Agreements On April 30, 2026, the Company entered into three Exchange Agreements (the “Exchanges”) with Streeterville.

Filing page SEC filing

AVTX

Avalo Therapeutics raises ~$405M in public offering; preliminary cash $82M as of March 31

Avalo Therapeutics, Inc. May 7, 2026, 7:59 PM ET other_material Items 1.01, 2.02, 7.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 2.02, 9.01 same event type: other_material similar materiality

This filing

On February 19, 2026, Vir Biotechnology, Inc. (Vir Bio) and Astellas US LLC (together with its subsidiaries and affiliates (including its indirect parent, Astellas Pharma Inc.), Astellas) entered into a Collaboration and License Agreement (the Agreement).

Comparable filing

On May 5, 2026, Avalo Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives of the underwriters listed in Schedule A thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of (a) 19,730,000 shares (the “Shares”) of its common stock, par value $0.001 per share (“Common Stock”), at a price to the public of $17.75 per Share, and (b) pre-funded warrants to purchase up to 1,400,000 shares of Common Stock (the “Pre-Funded Warrants”), at a price to the public of $17.749 per Pre-Funded Warrant, which represents the per share public offering price for the Shares less the $0.001 per share exercise price for each such Pre-Funded Warrant (the “Offering”).

Filing page SEC filing

HWH

HWH enters $10M PIPE with warrants at $0.50/share; terminates Hapi Metaverse acquisition

HWH International Inc. May 7, 2026, 7:59 PM ET other_material Items 1.01, 1.02, 5.02, 9.01

same fact type: material_agreement same SEC item: 1.01, 9.01 same event type: other_material similar materiality

This filing

On February 19, 2026, Vir Biotechnology, Inc. (Vir Bio) and Astellas US LLC (together with its subsidiaries and affiliates (including its indirect parent, Astellas Pharma Inc.), Astellas) entered into a Collaboration and License Agreement (the Agreement).

Comparable filing

On May 5, 2026, HWH International Inc., a Nevada corporation (the “Company”) entered into a term sheet (the “Term Sheet”) with Smart Dynamics Technology Limited, a company incorporated in the British Virgin Islands (the “Investor”), pursuant to which the Company has agreed to sell to the Investor, for an aggregate purchase price of $10,000,000

Filing page SEC filing

DGAC

Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE

DISCIPLINED GROWTH ACQUISITION Corp June 1, 2026, 4:15 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 3.02, 8.01, 9.01 same event type: other_material

This filing

On February 19, 2026, Vir Biotechnology, Inc. (Vir Bio) and Astellas US LLC (together with its subsidiaries and affiliates (including its indirect parent, Astellas Pharma Inc.), Astellas) entered into a Collaboration and License Agreement (the Agreement).

Comparable filing

A Share Rights Agreement, dated May 26, 2026, by and between the Company and Odyssey Transfer and Trust Company, as rights agent

Filing page SEC filing

SAGU

Shreya Acquisition Group closes $110M IPO, 11M units at $10 each on NYSE

Shreya Acquisition Group May 11, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 3.02, 8.01, 9.01 same event type: other_material

This filing

On February 19, 2026, Vir Biotechnology, Inc. (Vir Bio) and Astellas US LLC (together with its subsidiaries and affiliates (including its indirect parent, Astellas Pharma Inc.), Astellas) entered into a Collaboration and License Agreement (the Agreement).

Comparable filing

Private Units Subscription Agreement, dated May 6, 2026, by and between the Company and the Sponsor, a copy of which is attached as Exhibit 10.4 and incorporated herein by reference

Filing page SEC filing

Source: SEC EDGAR

accession 0001628280-26-010740

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.